AI can be used to detect and grade prostate cancer

byKarolinska InstitutetMicrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia,CC BY-SA 3.0Researchers at Karolinska Institutet in Sw

Updated on: December 22,2023

AI can be used to detect and grade prostate cancer

byKarolinska InstitutetMicrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia,CC BY-SA 3.0Researchers at Karolinska Institutet in Sw

Updated on:December 22,2023

Researchers clarify role of SMYD3 enzyme in prostate cancer progression

by Sarah Hansen,University of Maryland Baltimore CountySMYD3 loss impedes PCa progression.(A) Expression ofSMYD3mRNA from TCGA [GTEX normal (n= 105), TCGA tumor adjacent normal

Updated on: December 26,2023

Researchers clarify role of SMYD3 enzyme in prostate cancer progression

by Sarah Hansen,University of Maryland Baltimore CountySMYD3 loss impedes PCa progression.(A) Expression ofSMYD3mRNA from TCGA [GTEX normal (n= 105), TCGA tumor adjacent normal

Updated on:December 26,2023

Low-fat diet could be key to stopping cancer growth

by South Australian Health and Medical Research Institute (SAHMRI)Credit: Dan Gold on UnsplashNew research has found food could play a major role in stopping the growth of some cancers.It was previous

Updated on: December 20,2023

Low-fat diet could be key to stopping cancer growth

by South Australian Health and Medical Research Institute (SAHMRI)Credit: Dan Gold on UnsplashNew research has found food could play a major role in stopping the growth of some cancers.It was previous

Updated on:December 20,2023

Scientists develop powerful AI algorithm to gain new insights into deadly glioblastoma

by Sylvester Comprehensive Cancer CenterThe SPHINKS network for the precision targeting of master kinases in glioblastoma. Credit: Antonio Iavarone, M.D.Scientists at Sylvester Comprehensive Cancer Ce

Updated on: December 27,2023

Scientists develop powerful AI algorithm to gain new insights into deadly glioblastoma

by Sylvester Comprehensive Cancer CenterThe SPHINKS network for the precision targeting of master kinases in glioblastoma. Credit: Antonio Iavarone, M.D.Scientists at Sylvester Comprehensive Cancer Ce

Updated on:December 27,2023

New AI tool predicts risk for chronic pain in cancer patients

by Eric Hamilton,University of FloridaOverview of our transformer-based chronic pain prediction model: Three different data inputs are passed into dedicated encoders to generate a final vector t

Updated on: August 27,2024

New AI tool predicts risk for chronic pain in cancer patients

by Eric Hamilton,University of FloridaOverview of our transformer-based chronic pain prediction model: Three different data inputs are passed into dedicated encoders to generate a final vector t

Updated on:August 27,2024

Germany's BioNTech plans UK trial of mRNA cancer therapy

Scientists believe mRNA vaccines could be a game-changer against many diseases.German pharmaceutical company BioNTech, which developed a trailblazing COVID-19 vaccine, will trial a cancer treatment in

Updated on: December 20,2023

Germany's BioNTech plans UK trial of mRNA cancer therapy

Scientists believe mRNA vaccines could be a game-changer against many diseases.German pharmaceutical company BioNTech, which developed a trailblazing COVID-19 vaccine, will trial a cancer treatment in

Updated on:December 20,2023

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Updated on: December 22,2023

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Updated on:December 22,2023

Developing therapies for treatment-resistant prostate cancer: Small clinical trial shows 40% progression-free survival

byCedars-Sinai Medical CenterGraphical abstract. Credit:Molecular Therapy(2022). DOI: 10.1016/j.ymthe.2022.08.019Investigators from Cedars-Sinai Cancer have identified an investigati

Updated on: December 26,2023

Developing therapies for treatment-resistant prostate cancer: Small clinical trial shows 40% progression-free survival

byCedars-Sinai Medical CenterGraphical abstract. Credit:Molecular Therapy(2022). DOI: 10.1016/j.ymthe.2022.08.019Investigators from Cedars-Sinai Cancer have identified an investigati

Updated on:December 26,2023

Unraveling predisposition in bilateral Wilms tumor

bySt. Jude Children's Research HospitalSummary of Proposed Mechanisms for Bilateral Wilms tumor development. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-43730-0Ch

Updated on: December 30,2023

Unraveling predisposition in bilateral Wilms tumor

bySt. Jude Children's Research HospitalSummary of Proposed Mechanisms for Bilateral Wilms tumor development. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-43730-0Ch

Updated on:December 30,2023

Gene mutations should be tested routinely for ovarian cancer, say scientists

by Mike Addelman,University of ManchesterCredit: Unsplash/CC0 Public DomainScientists from The University of Manchester have shown that testing for two gene families linked to a lifetime epithel

Updated on: December 27,2023

Gene mutations should be tested routinely for ovarian cancer, say scientists

by Mike Addelman,University of ManchesterCredit: Unsplash/CC0 Public DomainScientists from The University of Manchester have shown that testing for two gene families linked to a lifetime epithel

Updated on:December 27,2023

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m

Updated on: February 18,2024

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m

Updated on:February 18,2024

When combined, a novel LSD1 inhibitor and an existing therapy enhance each other's anti-cancer effects

by Jaclyn Dunne,Medical University of South CarolinaGraphical abstract. Credit:European Journal of Medicinal Chemistry(2022). DOI: 10.1016/j.ejmech.2022.114818A Medical University of

Updated on: December 20,2023

When combined, a novel LSD1 inhibitor and an existing therapy enhance each other's anti-cancer effects

by Jaclyn Dunne,Medical University of South CarolinaGraphical abstract. Credit:European Journal of Medicinal Chemistry(2022). DOI: 10.1016/j.ejmech.2022.114818A Medical University of

Updated on:December 20,2023